Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy: An Analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Carotid Magnetic Resonance Imaging Substudy—Brief Report

OBJECTIVE—To assess whether Lp(a) (lipoprotein(a)) levels and other lipid levels were predictive of progression of atherosclerosis burden as assessed by carotid magnetic resonance imaging in subjects who have been treated with LDL-C (low-density lipoprotein cholesterol)–lowering therapy and particip...

Full description

Saved in:
Bibliographic Details
Published inArteriosclerosis, thrombosis, and vascular biology Vol. 38; no. 3; pp. 673 - 678
Main Authors Hippe, Daniel S., Phan, Binh P., Sun, Jie, Isquith, Daniel A., O’Brien, Kevin D., Crouse, John R., Anderson, Todd, Huston, John, Marcovina, Santica M., Hatsukami, Thomas S., Yuan, Chun, Zhao, Xue-Qiao
Format Journal Article
LanguageEnglish
Published United States American Heart Association, Inc 01.03.2018
Subjects
Online AccessGet full text

Cover

Loading…
Abstract OBJECTIVE—To assess whether Lp(a) (lipoprotein(a)) levels and other lipid levels were predictive of progression of atherosclerosis burden as assessed by carotid magnetic resonance imaging in subjects who have been treated with LDL-C (low-density lipoprotein cholesterol)–lowering therapy and participated in the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High TriglyceridesImpact on Global Health Outcomes). APPROACH AND RESULTS—AIM-HIGH was a randomized, double-blind study of subjects with established vascular disease, elevated triglycerides, and low HDL-C (high-density lipoprotein cholesterol). One hundred fifty-two AIM-HIGH subjects underwent both baseline and 2-year follow-up carotid artery magnetic resonance imaging. Plaque burden was measured by the percent wall volume (%WV) of the carotid artery. Associations between annualized change in %WV with baseline and on-study (1 year) lipid variables were evaluated using multivariate linear regression and the Bonferroni correction to account for multiple comparisons. Average %WV at baseline was 41.6±6.8% and annualized change in %WV over 2 years ranged from −3.2% to 3.7% per year (mean0.2±1.1% per year; P=0.032). Increases in %WV were significantly associated with higher baseline Lp(a) (β=0.34 per 1-SD increase of Lp(a); 95% confidence interval, 0.15–0.52; P<0.001) after adjusting for clinical risk factors and other lipid levels. On-study Lp(a) had a similar positive association with %WV progression (β=0.33; 95% confidence interval, 0.15–0.52; P<0.001). CONCLUSIONS—Despite intensive lipid therapy, aimed at aggressively lowering LDL-C to <70 mg/dL, carotid atherosclerosis continued to progress as assessed by carotid magnetic resonance imaging and that elevated Lp(a) levels were independent predictors of increases in atherosclerosis burden.
AbstractList To assess whether Lp(a) (lipoprotein(a)) levels and other lipid levels were predictive of progression of atherosclerosis burden as assessed by carotid magnetic resonance imaging in subjects who have been treated with LDL-C (low-density lipoprotein cholesterol)-lowering therapy and participated in the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes).OBJECTIVETo assess whether Lp(a) (lipoprotein(a)) levels and other lipid levels were predictive of progression of atherosclerosis burden as assessed by carotid magnetic resonance imaging in subjects who have been treated with LDL-C (low-density lipoprotein cholesterol)-lowering therapy and participated in the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes).AIM-HIGH was a randomized, double-blind study of subjects with established vascular disease, elevated triglycerides, and low HDL-C (high-density lipoprotein cholesterol). One hundred fifty-two AIM-HIGH subjects underwent both baseline and 2-year follow-up carotid artery magnetic resonance imaging. Plaque burden was measured by the percent wall volume (%WV) of the carotid artery. Associations between annualized change in %WV with baseline and on-study (1 year) lipid variables were evaluated using multivariate linear regression and the Bonferroni correction to account for multiple comparisons. Average %WV at baseline was 41.6±6.8% and annualized change in %WV over 2 years ranged from -3.2% to 3.7% per year (mean: 0.2±1.1% per year; P=0.032). Increases in %WV were significantly associated with higher baseline Lp(a) (β=0.34 per 1-SD increase of Lp(a); 95% confidence interval, 0.15-0.52; P<0.001) after adjusting for clinical risk factors and other lipid levels. On-study Lp(a) had a similar positive association with %WV progression (β=0.33; 95% confidence interval, 0.15-0.52; P<0.001).APPROACH AND RESULTSAIM-HIGH was a randomized, double-blind study of subjects with established vascular disease, elevated triglycerides, and low HDL-C (high-density lipoprotein cholesterol). One hundred fifty-two AIM-HIGH subjects underwent both baseline and 2-year follow-up carotid artery magnetic resonance imaging. Plaque burden was measured by the percent wall volume (%WV) of the carotid artery. Associations between annualized change in %WV with baseline and on-study (1 year) lipid variables were evaluated using multivariate linear regression and the Bonferroni correction to account for multiple comparisons. Average %WV at baseline was 41.6±6.8% and annualized change in %WV over 2 years ranged from -3.2% to 3.7% per year (mean: 0.2±1.1% per year; P=0.032). Increases in %WV were significantly associated with higher baseline Lp(a) (β=0.34 per 1-SD increase of Lp(a); 95% confidence interval, 0.15-0.52; P<0.001) after adjusting for clinical risk factors and other lipid levels. On-study Lp(a) had a similar positive association with %WV progression (β=0.33; 95% confidence interval, 0.15-0.52; P<0.001).Despite intensive lipid therapy, aimed at aggressively lowering LDL-C to <70 mg/dL, carotid atherosclerosis continued to progress as assessed by carotid magnetic resonance imaging and that elevated Lp(a) levels were independent predictors of increases in atherosclerosis burden.CONCLUSIONSDespite intensive lipid therapy, aimed at aggressively lowering LDL-C to <70 mg/dL, carotid atherosclerosis continued to progress as assessed by carotid magnetic resonance imaging and that elevated Lp(a) levels were independent predictors of increases in atherosclerosis burden.
To assess whether Lp(a) (lipoprotein(a)) levels and other lipid levels were predictive of progression of atherosclerosis burden as assessed by carotid magnetic resonance imaging in subjects who have been treated with LDL-C (low-density lipoprotein cholesterol)-lowering therapy and participated in the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes). AIM-HIGH was a randomized, double-blind study of subjects with established vascular disease, elevated triglycerides, and low HDL-C (high-density lipoprotein cholesterol). One hundred fifty-two AIM-HIGH subjects underwent both baseline and 2-year follow-up carotid artery magnetic resonance imaging. Plaque burden was measured by the percent wall volume (%WV) of the carotid artery. Associations between annualized change in %WV with baseline and on-study (1 year) lipid variables were evaluated using multivariate linear regression and the Bonferroni correction to account for multiple comparisons. Average %WV at baseline was 41.6±6.8% and annualized change in %WV over 2 years ranged from -3.2% to 3.7% per year (mean: 0.2±1.1% per year; =0.032). Increases in %WV were significantly associated with higher baseline Lp(a) (β=0.34 per 1-SD increase of Lp(a); 95% confidence interval, 0.15-0.52; <0.001) after adjusting for clinical risk factors and other lipid levels. On-study Lp(a) had a similar positive association with %WV progression (β=0.33; 95% confidence interval, 0.15-0.52; <0.001). Despite intensive lipid therapy, aimed at aggressively lowering LDL-C to <70 mg/dL, carotid atherosclerosis continued to progress as assessed by carotid magnetic resonance imaging and that elevated Lp(a) levels were independent predictors of increases in atherosclerosis burden.
OBJECTIVE—To assess whether Lp(a) (lipoprotein(a)) levels and other lipid levels were predictive of progression of atherosclerosis burden as assessed by carotid magnetic resonance imaging in subjects who have been treated with LDL-C (low-density lipoprotein cholesterol)–lowering therapy and participated in the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High TriglyceridesImpact on Global Health Outcomes). APPROACH AND RESULTS—AIM-HIGH was a randomized, double-blind study of subjects with established vascular disease, elevated triglycerides, and low HDL-C (high-density lipoprotein cholesterol). One hundred fifty-two AIM-HIGH subjects underwent both baseline and 2-year follow-up carotid artery magnetic resonance imaging. Plaque burden was measured by the percent wall volume (%WV) of the carotid artery. Associations between annualized change in %WV with baseline and on-study (1 year) lipid variables were evaluated using multivariate linear regression and the Bonferroni correction to account for multiple comparisons. Average %WV at baseline was 41.6±6.8% and annualized change in %WV over 2 years ranged from −3.2% to 3.7% per year (mean0.2±1.1% per year; P=0.032). Increases in %WV were significantly associated with higher baseline Lp(a) (β=0.34 per 1-SD increase of Lp(a); 95% confidence interval, 0.15–0.52; P<0.001) after adjusting for clinical risk factors and other lipid levels. On-study Lp(a) had a similar positive association with %WV progression (β=0.33; 95% confidence interval, 0.15–0.52; P<0.001). CONCLUSIONS—Despite intensive lipid therapy, aimed at aggressively lowering LDL-C to <70 mg/dL, carotid atherosclerosis continued to progress as assessed by carotid magnetic resonance imaging and that elevated Lp(a) levels were independent predictors of increases in atherosclerosis burden.
Author O’Brien, Kevin D.
Anderson, Todd
Hatsukami, Thomas S.
Crouse, John R.
Phan, Binh P.
Isquith, Daniel A.
Hippe, Daniel S.
Huston, John
Sun, Jie
Marcovina, Santica M.
Yuan, Chun
Zhao, Xue-Qiao
AuthorAffiliation From the Department of Radiology (D.S.H., J.S., C.Y.), Division of Cardiology (D.A.I., K.D.O., X.-Q.Z.), and Department of Surgery, Division of Vascular Surgery (T.S.H.), University of Washington School of Medicine, Seattle; Division of Cardiology, San Francisco General Hospital, University of California (B.A.P.P.); Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.R.C.); Libin Cardiovascular Institute of Alberta, University of Calgary, Canada (T.A.); Department of Radiology, Mayo Clinic, Rochester, MN (J.H.); and Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington, Seattle (S.M.M.)
AuthorAffiliation_xml – name: From the Department of Radiology (D.S.H., J.S., C.Y.), Division of Cardiology (D.A.I., K.D.O., X.-Q.Z.), and Department of Surgery, Division of Vascular Surgery (T.S.H.), University of Washington School of Medicine, Seattle; Division of Cardiology, San Francisco General Hospital, University of California (B.A.P.P.); Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.R.C.); Libin Cardiovascular Institute of Alberta, University of Calgary, Canada (T.A.); Department of Radiology, Mayo Clinic, Rochester, MN (J.H.); and Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington, Seattle (S.M.M.)
Author_xml – sequence: 1
  givenname: Daniel
  surname: Hippe
  middlename: S.
  fullname: Hippe, Daniel S.
  organization: From the Department of Radiology (D.S.H., J.S., C.Y.), Division of Cardiology (D.A.I., K.D.O., X.-Q.Z.), and Department of Surgery, Division of Vascular Surgery (T.S.H.), University of Washington School of Medicine, Seattle; Division of Cardiology, San Francisco General Hospital, University of California (B.A.P.P.); Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.R.C.); Libin Cardiovascular Institute of Alberta, University of Calgary, Canada (T.A.); Department of Radiology, Mayo Clinic, Rochester, MN (J.H.); and Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington, Seattle (S.M.M.)
– sequence: 2
  givenname: Binh
  surname: Phan
  middlename: P.
  fullname: Phan, Binh P.
– sequence: 3
  givenname: Jie
  surname: Sun
  fullname: Sun, Jie
– sequence: 4
  givenname: Daniel
  surname: Isquith
  middlename: A.
  fullname: Isquith, Daniel A.
– sequence: 5
  givenname: Kevin
  surname: O’Brien
  middlename: D.
  fullname: O’Brien, Kevin D.
– sequence: 6
  givenname: John
  surname: Crouse
  middlename: R.
  fullname: Crouse, John R.
– sequence: 7
  givenname: Todd
  surname: Anderson
  fullname: Anderson, Todd
– sequence: 8
  givenname: John
  surname: Huston
  fullname: Huston, John
– sequence: 9
  givenname: Santica
  surname: Marcovina
  middlename: M.
  fullname: Marcovina, Santica M.
– sequence: 10
  givenname: Thomas
  surname: Hatsukami
  middlename: S.
  fullname: Hatsukami, Thomas S.
– sequence: 11
  givenname: Chun
  surname: Yuan
  fullname: Yuan, Chun
– sequence: 12
  givenname: Xue-Qiao
  surname: Zhao
  fullname: Zhao, Xue-Qiao
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29301785$$D View this record in MEDLINE/PubMed
BookMark eNp9Ul1v0zAUDWiIfcAf4AH5sX3oZidNmuwt62CplGmIFXiMHOem9XDtYDud-saP4BfyS7hZxyR4mGTZvtI5x-f63OPgQBsNQfCO0VPGEnaWL79e5EWOxew0YjRK0pfBEYvD6WSaRMkB3uksm8TJNDwMjp27o5ROw5C-Dg7DLKJslsZHL0zZjfiYjErZmc4aD1JjPSYlbEE58slCI4XH06wsOCeNJqYlc45Q2ZDcr8EaJ9SwS0ekJrd9fQfCO_JN-vU_AC_FQGyk2XInesUtuZQOuAOCqgvtQTu5BYJWUHqJRN7tzkmucXG1G_TxaRQk-eJ6UiyuCjLa6_u1NZv6wcEgY7eg_eAU7VyD57VR-PTtTjcIg72x0tyT4rI8K-RqTZZWrtROgJUNuHOy2HQce0aBK2VqrkgBXCHnpvcCBdz4qf9rvtIw9PUZnNFcC0AyX0m9Gv7B-b7Z_f7568JKaBHSGevfBK9arhy8fTxPgi8fPyznxaS8uVrM83IiwiROJ-1sFrM6ok0LLQ1ZG0VNmIFgWRbFouZ0SiGJWJzUbUYbNg1TgAQaFoqUxnHdsOgkGO11MdQfPThfbaQToBTXYHpXsSzN4iilbIC-f4T29QaaqrNyw-2u-jskCAj3AIFROgvtE4TRapjE6nESsZhV-0lEUvofSUjPh1i85VI9T0321HujME33XfX3YKv1QwrPEf8AzYL79Q
CitedBy_id crossref_primary_10_1016_j_atherosclerosis_2018_08_037
crossref_primary_10_1016_j_addr_2020_07_019
crossref_primary_10_1016_j_pcad_2020_04_004
crossref_primary_10_1177_10760296221121282
crossref_primary_10_1161_CIRCULATIONAHA_120_052023
crossref_primary_10_1016_j_ihj_2019_03_004
crossref_primary_10_1016_j_amjcard_2024_09_006
crossref_primary_10_3390_jcdd8020011
crossref_primary_10_1016_j_clinsp_2022_100107
crossref_primary_10_1097_MOL_0000000000000889
crossref_primary_10_1007_s11883_019_0773_y
crossref_primary_10_1093_eurjpc_zwab052
crossref_primary_10_1080_10641963_2019_1619754
crossref_primary_10_1016_j_acvd_2024_07_061
crossref_primary_10_1080_10408363_2025_2462817
crossref_primary_10_1161_STROKEAHA_120_030616
crossref_primary_10_1016_j_pharmthera_2020_107592
crossref_primary_10_1038_s41467_021_21390_2
crossref_primary_10_1016_j_atherosclerosis_2021_05_008
crossref_primary_10_1161_ATVBAHA_120_313609
crossref_primary_10_36485_1561_6274_2021_25_1_31_46
crossref_primary_10_18087_cardio_2019_12_n727
crossref_primary_10_1186_s12872_021_02038_x
crossref_primary_10_1016_j_amjmed_2018_08_019
crossref_primary_10_3389_fcvm_2021_742935
crossref_primary_10_1161_ATVBAHA_118_312267
crossref_primary_10_1016_j_arcmed_2020_12_003
crossref_primary_10_3390_ijerph20186721
crossref_primary_10_1161_ATVBAHA_118_311999
crossref_primary_10_1161_ATVBAHA_119_312001
crossref_primary_10_3390_ijms222111419
Cites_doi 10.1161/STROKEAHA.113.001461
10.1001/jama.1987.03390230069027
10.1016/j.amjcard.2014.08.001
10.1161/ATVBAHA.112.251306
10.1016/j.jacc.2013.06.051
10.1161/STROKEAHA.111.624684
10.1194/jlr.R052258
10.1056/NEJMoa011090
10.1056/NEJM199011083231901
10.7326/0003-4819-142-2-200501180-00008
10.1161/STROKEAHA.114.005752
10.1093/eurheartj/ehq386
10.1161/CIRCULATIONAHA.107.715698
10.1016/j.jacc.2010.03.017
10.1001/jama.2009.1063
10.1016/j.atherosclerosis.2017.06.026
10.1056/NEJMoa0902604
10.1016/j.atherosclerosis.2015.11.032
10.1056/NEJMoa1501031
10.1194/jlr.P030890
10.1056/NEJMoa1615664
10.1161/01.CIR.102.10.1082
10.1161/01.CIR.0000148955.19792.8D
10.1038/ncpcardio1456
10.1194/jlr.M040733
10.1056/NEJMoa1500858
10.2217/clp.13.9
10.1016/j.amjcard.2014.01.426
10.1001/jama.2016.16951
10.1001/jama.2009.801
10.1056/NEJMoa1107579
ContentType Journal Article
Copyright 2018 American Heart Association, Inc.
Copyright_xml – notice: 2018 American Heart Association, Inc.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1161/ATVBAHA.117.310368
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1524-4636
EndPage 678
ExternalDocumentID 29301785
10_1161_ATVBAHA_117_310368
10.1161/ATVBAHA.117.310368
Genre Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIDDK NIH HHS
  grantid: P30 DK017047
– fundername: NHLBI NIH HHS
  grantid: R01 HL088214
– fundername: NHLBI NIH HHS
  grantid: R01 HL063895
– fundername: NHLBI NIH HHS
  grantid: T32 HL007828
GroupedDBID ---
.3C
.55
.GJ
.Z2
01R
0R~
1J1
23N
2WC
3O-
40H
4Q1
4Q2
4Q3
53G
5GY
5RE
5VS
71W
77Y
7O~
AAAAV
AAAXR
AAGIX
AAHPQ
AAIQE
AAMOA
AAMTA
AAQKA
AARTV
AASCR
AASOK
AAXQO
ABASU
ABBUW
ABDIG
ABJNI
ABPXF
ABQRW
ABVCZ
ABXVJ
ABZAD
ABZZY
ACCJW
ACDDN
ACEWG
ACGFS
ACGOD
ACILI
ACLDA
ACPRK
ACWDW
ACWRI
ACXJB
ACXNZ
ACZKN
ADBBV
ADFPA
ADGGA
ADHPY
ADNKB
AE3
AE6
AEETU
AENEX
AFBFQ
AFDTB
AFFNX
AFUWQ
AGINI
AHJKT
AHMBA
AHOMT
AHQNM
AHRYX
AHVBC
AIJEX
AINUH
AJCLO
AJIOK
AJNWD
AJNYG
AJZMW
AKCTQ
AKULP
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AOQMC
AYCSE
BAWUL
BOYCO
BQLVK
BS7
C1A
C45
CS3
DIK
DIWNM
DUNZO
E.X
E3Z
EBS
EEVPB
EJD
ERAAH
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FL-
FRP
FW0
GNXGY
GQDEL
GX1
H0~
H13
HLJTE
HZ~
IKREB
IKYAY
IN~
IPNFZ
J5H
JF9
JG8
JK3
JK8
K8S
KD2
KMI
KQ8
L-C
L7B
N9A
N~7
N~B
N~M
O9-
OAG
OAH
OB2
OCUKA
ODA
OL1
OLG
OLH
OLU
OLV
OLY
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P-K
P2P
PQQKQ
PZZ
RAH
RIG
RLZ
S4R
S4S
T8P
TEORI
TR2
TSPGW
V2I
VVN
W3M
W8F
WOQ
WOW
X3V
X3W
X7M
XXN
XYM
YFH
ZGI
ZZMQN
AAYXX
ADGHP
CITATION
ACIJW
AWKKM
CGR
CUY
CVF
ECM
EIF
NPM
OK1
OLW
RHF
7X8
ID FETCH-LOGICAL-c2658-f7751b30dfef021f33d29ec19935cba040e63156bf90d1428ee6ed12c8055bd13
ISSN 1079-5642
1524-4636
IngestDate Fri Jul 11 07:41:57 EDT 2025
Wed Feb 19 02:31:25 EST 2025
Thu Apr 24 22:58:08 EDT 2025
Tue Jul 01 02:21:59 EDT 2025
Fri May 16 03:42:25 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords atherosclerosis
lipids
risk factors
lipoprotein
lp(a)
triglycerides
lipoprotein(a)
Language English
License 2018 American Heart Association, Inc.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c2658-f7751b30dfef021f33d29ec19935cba040e63156bf90d1428ee6ed12c8055bd13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
PMID 29301785
PQID 1989538011
PQPubID 23479
PageCount 6
ParticipantIDs proquest_miscellaneous_1989538011
pubmed_primary_29301785
crossref_primary_10_1161_ATVBAHA_117_310368
crossref_citationtrail_10_1161_ATVBAHA_117_310368
wolterskluwer_health_10_1161_ATVBAHA_117_310368
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-March
PublicationDateYYYYMMDD 2018-03-01
PublicationDate_xml – month: 03
  year: 2018
  text: 2018-March
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Arteriosclerosis, thrombosis, and vascular biology
PublicationTitleAlternate Arterioscler Thromb Vasc Biol
PublicationYear 2018
Publisher American Heart Association, Inc
Publisher_xml – name: American Heart Association, Inc
References e_1_3_4_3_2
e_1_3_4_2_2
e_1_3_4_9_2
e_1_3_4_8_2
e_1_3_4_7_2
e_1_3_4_6_2
e_1_3_4_5_2
e_1_3_4_4_2
e_1_3_4_22_2
e_1_3_4_23_2
e_1_3_4_20_2
e_1_3_4_21_2
e_1_3_4_26_2
e_1_3_4_27_2
e_1_3_4_24_2
e_1_3_4_25_2
e_1_3_4_28_2
e_1_3_4_29_2
e_1_3_4_30_2
e_1_3_4_11_2
e_1_3_4_12_2
e_1_3_4_32_2
e_1_3_4_10_2
e_1_3_4_31_2
e_1_3_4_15_2
e_1_3_4_16_2
e_1_3_4_13_2
e_1_3_4_14_2
e_1_3_4_19_2
e_1_3_4_17_2
e_1_3_4_18_2
References_xml – ident: e_1_3_4_11_2
  doi: 10.1161/STROKEAHA.113.001461
– ident: e_1_3_4_13_2
  doi: 10.1001/jama.1987.03390230069027
– ident: e_1_3_4_8_2
  doi: 10.1016/j.amjcard.2014.08.001
– ident: e_1_3_4_23_2
  doi: 10.1161/ATVBAHA.112.251306
– ident: e_1_3_4_7_2
  doi: 10.1016/j.jacc.2013.06.051
– ident: e_1_3_4_6_2
  doi: 10.1161/STROKEAHA.111.624684
– ident: e_1_3_4_32_2
  doi: 10.1194/jlr.R052258
– ident: e_1_3_4_15_2
  doi: 10.1056/NEJMoa011090
– ident: e_1_3_4_14_2
  doi: 10.1056/NEJM199011083231901
– ident: e_1_3_4_16_2
  doi: 10.7326/0003-4819-142-2-200501180-00008
– ident: e_1_3_4_12_2
  doi: 10.1161/STROKEAHA.114.005752
– ident: e_1_3_4_3_2
  doi: 10.1093/eurheartj/ehq386
– ident: e_1_3_4_4_2
  doi: 10.1161/CIRCULATIONAHA.107.715698
– ident: e_1_3_4_17_2
  doi: 10.1016/j.jacc.2010.03.017
– ident: e_1_3_4_21_2
  doi: 10.1001/jama.2009.1063
– ident: e_1_3_4_27_2
  doi: 10.1016/j.atherosclerosis.2017.06.026
– ident: e_1_3_4_22_2
  doi: 10.1056/NEJMoa0902604
– ident: e_1_3_4_9_2
  doi: 10.1016/j.atherosclerosis.2015.11.032
– ident: e_1_3_4_29_2
  doi: 10.1056/NEJMoa1501031
– ident: e_1_3_4_25_2
  doi: 10.1194/jlr.P030890
– ident: e_1_3_4_30_2
  doi: 10.1056/NEJMoa1615664
– ident: e_1_3_4_2_2
  doi: 10.1161/01.CIR.102.10.1082
– ident: e_1_3_4_18_2
  doi: 10.1161/01.CIR.0000148955.19792.8D
– ident: e_1_3_4_31_2
  doi: 10.1038/ncpcardio1456
– ident: e_1_3_4_26_2
  doi: 10.1194/jlr.M040733
– ident: e_1_3_4_28_2
  doi: 10.1056/NEJMoa1500858
– ident: e_1_3_4_24_2
  doi: 10.2217/clp.13.9
– ident: e_1_3_4_19_2
  doi: 10.1016/j.amjcard.2014.01.426
– ident: e_1_3_4_20_2
  doi: 10.1001/jama.2016.16951
– ident: e_1_3_4_5_2
  doi: 10.1001/jama.2009.801
– ident: e_1_3_4_10_2
  doi: 10.1056/NEJMoa1107579
SSID ssj0004220
Score 2.4343972
Snippet OBJECTIVE—To assess whether Lp(a) (lipoprotein(a)) levels and other lipid levels were predictive of progression of atherosclerosis burden as assessed by...
To assess whether Lp(a) (lipoprotein(a)) levels and other lipid levels were predictive of progression of atherosclerosis burden as assessed by carotid magnetic...
SourceID proquest
pubmed
crossref
wolterskluwer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 673
SubjectTerms Adult
Aged
Aged, 80 and over
Biomarkers - blood
Carotid Arteries - diagnostic imaging
Carotid Arteries - drug effects
Carotid Arteries - pathology
Carotid Artery Diseases - blood
Carotid Artery Diseases - diagnostic imaging
Carotid Artery Diseases - drug therapy
Carotid Artery Diseases - pathology
Cholesterol, LDL - blood
Double-Blind Method
Female
Humans
Hypolipidemic Agents - therapeutic use
Lipoprotein(a) - blood
Magnetic Resonance Angiography
Male
Middle Aged
Plaque, Atherosclerotic
Predictive Value of Tests
Risk Factors
Time Factors
Treatment Outcome
Title Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy: An Analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Carotid Magnetic Resonance Imaging Substudy—Brief Report
URI https://www.ncbi.nlm.nih.gov/pubmed/29301785
https://www.proquest.com/docview/1989538011
Volume 38
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEF7aIiEQQtyES4PEQ6vIbXzG6Zt7kYDTgppA3ywf69bQOqFJVMG_4Z8ys7s-klZV4cVKnHh3vTvf7szuNzOMvUczupOGlqFFphNqVppwzU2MjhYZ3KblwkqFl2t_3-kOrY9H9tHS8p8aa2k2jdbj31f6lfzPqOI9HFfykv2HkS0LxRv4GccXrzjCeL3RGPtj1A9DYdgbrp-NRyLqApn64i794BMpaEJMiySLp-QXcCyZr7n0zMIHsqTpkRo4mmDxeM0ERRZnlO-C6fGNdmrrf6AQr9vzNNYdecxDJw8VJ57SYidE6aCwBWoDsh4DRTi19Ppat_ehSy8g66C8DWeRaEVvgY_Z51MUWYrKfajiLMjG-aOLZnfHx34k1kpzcJ4dn_6KcQASSfjrKU9QGT9ERVPG5w5mUxwVmic7ZU_0w-Oc_DrFuUYu_Cl6ZzKTE82xFIxX2zrPeKpMl7py7xE9Nqu6kcS3ep2CJ1t2mop_VW3-j8e88vqv9qQ_n8hN6q0sP6E-LD3yDmfSsSbjFcB_ztROmSrFq2_r6G7FaytWIsPSKJqbXKivuKeWL9OtwdSsrUWOzBFzeY10aI30Bl-3vK5Hh_brlGtOJjeaD0i-fxDsDX0_GOweDZbZbQMtMUoS8ulLLSC_ISKfli0r_NIcfeNyDfO63yWD7h67fzEijsjkh3ARqSl6g4fsgbLQwJNwe8SWeP6Y3ekrDsqTW2f-eDVcg9Ua3vD7GkikgUIa1JAGoxSUfMEC0iDLoUAakDDDAtJgHmmgkAZYaok0EEgDhbRN8HIocEZVY4FQ4AxWF1EGdZRRc0qUQYEy2TBEGSDKNghjMIexTZAIo0ZJhIFEGBQIWyvfv8AXlPgChS-YxxdIfD1lw73dwXZXU0lbtNhAa0ZL221bj8xWkvIU7YfUNHHq5zHxhO04ClFn4I6p206UdloJhXvk3OGJbsRuy7ajRDefsZV8lPMXDMyWm6IF0Ylcx7WSdjtsm-1O1EatI7JS1zYaTC_EKYhVRgNKrHMaiJ0NRw-UCFJGg0CKYIM1y2fGMp7Ptf9-V0hpgMsunaWGOR_NJgFRTVFXRO2owZ5L8S3LQwsK9RzXbrCNOXkOpGv7NfW9vEF9r9jdar54zVam5zP-Bg2jafRWQPMvNcdsdg
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Lp%28a%29+%28Lipoprotein%28a%29%29+Levels+Predict+Progression+of+Carotid+Atherosclerosis+in+Subjects+With+Atherosclerotic+Cardiovascular+Disease+on+Intensive+Lipid+Therapy%3A+An+Analysis+of+the+AIM-HIGH+%28Atherothrombosis+Intervention+in+Metabolic+Syndrome+With+Low+HDL%2FHigh+Triglycerides%3A+Impact+on+Global+Health+Outcomes%29+Carotid+Magnetic+Resonance+Imaging+Substudy-Brief+Report&rft.jtitle=Arteriosclerosis%2C+thrombosis%2C+and+vascular+biology&rft.au=Hippe%2C+Daniel+S&rft.au=Phan%2C+Binh+An+P&rft.au=Sun%2C+Jie&rft.au=Isquith%2C+Daniel+A&rft.date=2018-03-01&rft.issn=1524-4636&rft.eissn=1524-4636&rft.volume=38&rft.issue=3&rft.spage=673&rft_id=info:doi/10.1161%2FATVBAHA.117.310368&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1079-5642&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1079-5642&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1079-5642&client=summon